These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 8656257)
41. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862 [TBL] [Abstract][Full Text] [Related]
42. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H; Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518 [TBL] [Abstract][Full Text] [Related]
43. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators. Clahsen PC; van de Velde CJ; Welvaart K; van Driel OJ; Sylvester RJ J Clin Oncol; 1995 Jan; 13(1):33-41. PubMed ID: 7799039 [TBL] [Abstract][Full Text] [Related]
44. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F; Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286 [TBL] [Abstract][Full Text] [Related]
45. Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA). Boccardo F; Rubagotti A; Amoroso D; Perrotta A; Sismondi P; Farris A; Mesiti M; Gallo L; Pacini P; Villa E; Agostara B Cancer Invest; 1997; 15(6):505-12. PubMed ID: 9412655 [TBL] [Abstract][Full Text] [Related]
46. Adjuvant chemotherapy in early breast cancer. Ejlertsen B Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018 [TBL] [Abstract][Full Text] [Related]
47. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. Colleoni M; Bonetti M; Coates AS; Castiglione-Gertsch M; Gelber RD; Price K; Rudenstam CM; Lindtner J; Collins J; Thürlimann B; Holmberg S; Veronesi A; Marini G; Goldhirsch A J Clin Oncol; 2000 Feb; 18(3):584-90. PubMed ID: 10653873 [TBL] [Abstract][Full Text] [Related]
48. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417 [TBL] [Abstract][Full Text] [Related]
49. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983 [TBL] [Abstract][Full Text] [Related]
50. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer. Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522 [TBL] [Abstract][Full Text] [Related]
51. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
52. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. Amadori D; Nanni O; Marangolo M; Pacini P; Ravaioli A; Rossi A; Gambi A; Catalano G; Perroni D; Scarpi E; Giunchi DC; Tienghi A; Becciolini A; Volpi A J Clin Oncol; 2000 Sep; 18(17):3125-34. PubMed ID: 10963641 [TBL] [Abstract][Full Text] [Related]
53. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS; J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194 [TBL] [Abstract][Full Text] [Related]
54. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820 [TBL] [Abstract][Full Text] [Related]
55. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501 [TBL] [Abstract][Full Text] [Related]
56. Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer. Li HC; Wen XF; Hou YF; Shen KW; Wu J; Lu JS; Shen ZZ; Shao ZM Asian J Surg; 2003 Jul; 26(3):163-8. PubMed ID: 12925292 [TBL] [Abstract][Full Text] [Related]
57. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Kaufmann M; Jonat W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; Schumacher M; Sauerbrei W; Eur J Cancer; 2003 Aug; 39(12):1711-7. PubMed ID: 12888366 [TBL] [Abstract][Full Text] [Related]
58. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy. Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377 [TBL] [Abstract][Full Text] [Related]
59. Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial). Ohashi Y; Watanabe T; Sano M; Koyama H; Inaji H; Suzuki T Breast Cancer Res Treat; 2010 Feb; 119(3):633-41. PubMed ID: 19936917 [TBL] [Abstract][Full Text] [Related]
60. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ; N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]